{
    "clinical_study": {
        "@rank": "136184", 
        "arm_group": [
            {
                "arm_group_label": "telmisartan + HCTZ + amlodipine", 
                "arm_group_type": "Experimental", 
                "description": "telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and  hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"
            }, 
            {
                "arm_group_label": "telmisartan + HCTZ + placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and  hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-centre, randomised, double-blind, active-controlled, parallel-group\n      comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg +\n      hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+\n      hydrochlorothiazide 12.5 mg (T80/H12.5 mg) in blood pressure lowering effect at week 8, the\n      end of the double-blind period in essential hypertensive patients who fail to respond\n      adequately to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg.\n\n      Patients are assigned to one of the two groups after a 6-week open-label run-in period\n      taking T80/H12.5 mg.\n\n      In addition the long-term safety of telmisartan 80 mg+ amlodipine 5 mg+ hydrochlorothiazide\n      12.5 mg will be evaluated in a 52-week extension period.\n\n      In the 52-week open label extension period patients who are assigned to the T80/A5/H12.5 mg\n      group continue the T80/A5/H12.5 mg therapy, and patients who are assigned to the T80/ /H12.5\n      mg group change to the T80/A5/H12.5 mg therapy."
        }, 
        "brief_title": "Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs\n             and mean seated diastolic blood pressure (DBP) must be >=90 and <=114 mmHg and mean\n             seated systolic blood pressure (SBP) must be =<200 mmHg\n\n          2. Able to stop all current antihypertensive drugs (other than study medication) from\n             Visit 1b through the end of the trial without risk to the patient based on the\n             investigator's opinion\n\n          3. Age 20 years or older\n\n        Exclusion criteria:\n\n          1. Patients with known or suspected secondary hypertension\n\n          2. Patients with clinically relevant cardiac arrhythmia\n\n          3. Congestive heart failure with New York Heart Association (NYHA) functional class\n             III-IV\n\n          4. Patients with recent cardiovascular events\n\n          5. Patients with recent stroke events\n\n          6. Patients with a history of sudden deterioration of renal function with angiotensin II\n             receptor blockers or angiotensin converting enzyme inhibitors; or patients with\n             post-renal transplant or post-nephrectomy\n\n          7. Patients with hepatic and/or renal dysfunction\n\n          8. Pre-menopausal women who are nursing or pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911780", 
            "org_study_id": "1348.2"
        }, 
        "intervention": [
            {
                "arm_group_label": "telmisartan + HCTZ + placebo", 
                "description": "placebo matching amlodipine capsule", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "telmisartan + HCTZ + placebo", 
                "description": "FDC tablet", 
                "intervention_name": "telmisartan + HCTZ", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "telmisartan + HCTZ + amlodipine", 
                "description": "FDC tablet", 
                "intervention_name": "telmisartan + HCTZ", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "telmisartan + HCTZ + amlodipine", 
                "description": "capsule", 
                "intervention_name": "amlodipine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hydrochlorothiazide", 
                "Amlodipine", 
                "Telmisartan", 
                "Benzoates"
            ]
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chiyoda-ku, Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.020 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku, Fukuoka, Fukuoka", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.008 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku,Kobe, Hyogo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.018 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku,Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.013 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku,Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.021 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku,Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.006 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hirakata, Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.012 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kasaoka, Okayama", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.011 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kawasaki, Kanagawa", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.001 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kita-ku, Osaka-shi, Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.019 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiyota-ku, Sapporo-shi, Hokkaido", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.014 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kumamoto, Kumamoto", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.002 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nakano-ku,Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.007 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nishi-ku, Fukuoka, Fukuoka", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.009 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Takatsuki, Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.005 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uji, Kyoto", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.016 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yoshikawa, Saitama", 
                        "country": "Japan"
                    }, 
                    "name": "1348.2.010 Boehringer Ingelheim Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg, Followed by a 52 Weeks Extension Study to Assess Long Term Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in mean seated diastolic blood pressure (DBP) at trough after 8 weeks of the double-blind period", 
            "safety_issue": "No", 
            "time_frame": "baseline and week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911780"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The number of patients with DBP<90 mmHg and SBP<140 mmHg as seated blood pressure at trough after 8 weeks of the double-blind period", 
                "safety_issue": "No", 
                "time_frame": "week 8"
            }, 
            {
                "measure": "The number of patients with DBP<90 mmHg and SBP<140 mmHg as seated blood pressure at trough after 52weeks of the extension period", 
                "safety_issue": "No", 
                "time_frame": "week 52"
            }, 
            {
                "measure": "Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period", 
                "safety_issue": "No", 
                "time_frame": "baseline and week 8"
            }, 
            {
                "measure": "Change from baseline in mean seated DBP at trough after 52weeks of the extension period", 
                "safety_issue": "No", 
                "time_frame": "baseline and week 52"
            }, 
            {
                "measure": "Change from baseline in mean seated SBP at trough after 52weeks of the extension period", 
                "safety_issue": "No", 
                "time_frame": "baseline and week 52"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}